Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Taiho Oncology, Inc.
This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications. Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or futibatinib plus fulvestrant in Cohort 4, as follows: * Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification * Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification * Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification * Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted